Dora Pinto
YOU?
Author Swipe
View article: Caregivers' attitudes toward school-based vaccination programs: A comparison of COVID-19, HPV, influenza, and dengue vaccines in Brazil
Caregivers' attitudes toward school-based vaccination programs: A comparison of COVID-19, HPV, influenza, and dengue vaccines in Brazil Open
At least one in five Brazilian caregivers of school-aged children is hesitant about participating in COVID-19 school vaccine programs, whereas one in 10 is hesitant about influenza, HPV, and dengue vaccines.
View article: Neutralization, effector function and immune imprinting of Omicron variants
Neutralization, effector function and immune imprinting of Omicron variants Open
Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots in the receptor-binding domain 1 (RBD) of the spike protein. The effects of these mutations on viral infection and transmission and the efficacy of v…
View article: Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants Open
Currently circulating SARS-CoV-2 variants acquired convergent mutations at receptor-binding domain (RBD) hot spots 1 . Their impact on viral infection, transmission, and efficacy of vaccines and therapeutics remains poorly understood. Here…
View article: Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages Open
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boost…
View article: ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies
ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies Open
The coronavirus spike glycoprotein attaches to host receptors and mediates viral fusion. Using a broad screening approach, we isolated seven monoclonal antibodies (mAbs) that bind to all human-infecting coronavirus spike proteins from seve…
View article: Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages Open
SARS-CoV-2 Omicron sublineages carry distinct spike mutations and represent an antigenic shift resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity or vaccine boosters result in pot…
View article: ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies
ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies Open
Coronaviruses use diverse Spike (S) glycoproteins to attach to host receptors and fuse with target cells. Using a broad screening approach, we isolated from SARS-CoV-2 immune donors seven monoclonal antibodies (mAbs) that bind to all human…
View article: Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry Open
Understanding broadly neutralizing sarbecovirus antibody responses is key to developing countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and future zoonotic sarbecoviruses. We describe the isola…
View article: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Open
SUMMARY The recently emerged SARS-CoV-2 Omicron variant harbors 37 amino acid substitutions in the spike (S) protein, 15 of which are in the receptor-binding domain (RBD), thereby raising concerns about the effectiveness of available vacci…
View article: Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry Open
Understanding broadly neutralizing sarbecovirus antibody responses is key to developing countermeasures effective against SARS-CoV-2 variants and future spillovers of other sarbecoviruses. Here we describe the isolation and characterizatio…
View article: Broad betacoronavirus neutralization by a stem helix–specific human antibody
Broad betacoronavirus neutralization by a stem helix–specific human antibody Open
Targeting a range of betacoranaviruses In the past 20 years, three highly pathogenic β-coronaviruses have crossed from animals to humans, including the most recent: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A spike prot…
View article: SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern Open
SARS-CoV-2 from alpha to epsilon As battles to contain the COVID-19 pandemic continue, attention is focused on emerging variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that have been deemed variants of co…
View article: A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery
A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery Open
The repeated spillovers of β-coronaviruses in humans along with the rapid emergence of SARS-CoV-2 escape variants highlight the need to develop broad coronavirus therapeutics and vaccines. Five monoclonal antibodies (mAbs) were isolated fr…
View article: SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies Open
The SARS-CoV-2 B.1.617.2 (Delta) variant was first identified in the state of Maharashtra in late 2020 and spread throughout India, displacing the B.1.1.7 (Alpha) variant and other pre-existing lineages, including B.1.617.1 that was detect…
View article: Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody Open
The recent emergence of SARS-CoV-2 variants of concern (VOC) and the recurrent spillovers of coronaviruses in the human population highlight the need for broadly neutralizing antibodies that are not affected by the ongoing antigenic drift …
View article: Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape.
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape. Open
An ideal anti-SARS-CoV-2 antibody would resist viral escape 1-3 , have activity against diverse SARS-related coronaviruses 4-7 , and be highly protective through viral neutralization 8-11 and effector functions 12,13 . Understanding how th…
View article: Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape Open
An ideal anti-SARS-CoV-2 antibody would resist viral escape 1–3 , have activity against diverse SARS-related coronaviruses 4–7 , and be highly protective through viral neutralization 8–11 and effector functions 12,13 . Understanding how th…
View article: SARS-CoV-2 immune evasion by variant B.1.427/B.1.429
SARS-CoV-2 immune evasion by variant B.1.427/B.1.429 Open
SARS-CoV-2 entry is mediated by the spike (S) glycoprotein which contains the receptor-binding domain (RBD) and the N-terminal domain (NTD) as the two main targets of neutralizing antibodies (Abs). A novel variant of concern (VOC) named CA…
View article: The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2
The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2 Open
Sotrovimab (VIR-7831) and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sotrovimab and VIR-7832 were derived from a parent antibody (…